Price Alert

TScan Therapeutics Inc. (TCRX)

NASDAQ: TCRX · Real-Time Price · USD

1.79

-0.01 (-0.56%)

At close: Aug 18, 2025, 3:59 PM

1.79

0.00%

After-hours: Aug 18, 2025, 06:16 PM EDT

-0.56% (1D)

Bid	1.7
Market Cap	101.3M
Revenue (ttm)	4.42M
Net Income (ttm)	-131.48M
EPS (ttm)	-1.1
PE Ratio (ttm)	-1.63
Forward PE	-1.39
Analyst	Buy

Ask	2
Volume	99,085
Avg. Volume (20D)	572,432
Open	1.81
Previous Close	1.80
Day's Range	1.76 - 1.84
52-Week Range	1.02 - 6.22
Beta	0.99

About TCRX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TCRX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TCRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

TScan Therapeutics has released their quartely earnings on Aug 12, 2025:

Revenue of $3.08M exceeds estimates by $1.51M, with 473.88% YoY growth.

EPS of -0.28 exceeds estimates by 0.03, with 0.00% YoY growth.

Next Earnings Release

TScan Therapeutics Inc. is scheduled to release its earnings on Nov 11, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

News

1 week ago · zacks.com

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.28 per share a year ago.

2 months ago · https://www.defenseworld.net

Squarepoint Ops LLC Makes New $59,000 Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX)

Squarepoint Ops LLC purchased a new position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) during the fourth quarter, according to the company in its most recent disclosure w...